Target intelligence / Profile preview

Coiled-coil domain-containing protein 39 (CCDC39)

Target
CCDC39
Molecular classification
Other (structural/axonal protein), Molecular ruler complex subunit, Not a receptor, enzyme, transporter, ion channel, transcription factor, or histone modification
01

Overview

Coiled-coil domain-containing protein 39 (CCDC39) is a structural protein localized to the axonemes of motile cilia and flagella. It forms a heterodimer complex with CCDC40, functioning as a molecular ruler responsible for arranging inner dynein arm complexes and the dynein regulatory complex at a precise 96-nm spacing in cilia. This organization is crucial for normal ciliary motility, which underlies physiological functions such as mucociliary clearance in airways, left-right axis determination in embryogenesis, and sperm tail motility. Mutations in CCDC39 disrupt this architecture, resulting in primary ciliary dyskinesia with characteristic respiratory disease, laterality defects, and male infertility. CCDC39 mutations are also notable for causing severe phenotypes due to both motility-dependent and motility-independent cellular defects, including structural loss of multiple ciliary components. There are currently no drugs targeting CCDC39, but it is considered a key gene for molecular diagnosis and may be a candidate for future gene therapies.

Other names
CCDC39Coiled-coil domain-containing 39FAP59CILD14CFAP59DKFZp434A128
02

Mechanism of action

None applicable, as no drugs are known to target CCDC39 directly.

03

Biological functions

Ciliary and flagellar motilityAssembly of the dynein regulatory complexInner dynein arm assemblyOrganization of the 96-nm repeat units in motile ciliaStructural support and arrangement of axonemal complexesCell fate determination in multiciliated cells (via disease mutations)
04

Disease associations

Primary ciliary dyskinesia (PCD), subtype 14Respiratory disease (chronic infections associated with PCD)Male infertility (due to asthenozoospermia and flagellar abnormalities)Laterality defects (situs inversus, heterotaxy)Hydrocephalus (rare, broader cilia-related phenotype)
05

Safety considerations

Not applicable for direct therapeutics targeting CCDC39.Gene therapy is researched as a future therapeutic approach, but clinical safety profiles remain undetermined
06

Interacting drugs

None currently known or reported
07

Biomarkers

Presence of biallelic (often homozygous truncating) mutations in CCDC39 for diagnosis and molecular subtyping of primary ciliary dyskinesiaQuantitative ciliary beating abnormalities (e.g., altered beat pattern, ciliary ultrastructure in PCD)

Beyond the preview

Go deeper on Coiled-coil domain-containing protein 39 (CCDC39).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coiled-coil domain-containing protein 39 (CCDC39).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call